Skip to main content
Premium Trial:

Request an Annual Quote

Caliper's Shares Rise 16.8 Percent on Strong Q2 Results

Shares of Caliper Life Sciences rose 16.8 percent for the five-day trading week ended Tuesday after reporting last week that its second-quarter revenues rose 45 percent (see related article). The firm also said that it had received a key patent for its optical imaging IP estate.
 
Sequenom led decliners in the BCW Index for the week, falling 16.5 percent for the tracking period. Overall, the Index was down 1.6 percent, with shares of 14 companies in the Index losing value during the week.
 
The Dow Jones Industrial Average experienced another difficult week, declining 3.5 percent. The Nasdaq dropped 2.4 percent, while the Nasdaq Biotech Index dropped 1.2 percent.

 
 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price
(Aug. 14, 2007)
Starting Price
(Aug. 7, 2007)
% change
Affymetrix
AFFX
24.87
27.45
-9.40
Agilent
A
36.33
38.3
-5.14
Applied Biosystems
ABI
33.06
32.54
1.60
Beckman
BEC
70.84
71.46
-0.87
Becton Dickinson
BDX
75.74
77.6
-2.40
Bio-Rad
BIO
79.58
77.16
3.14
Bruker
BRKR
7.54
7.46
1.07
Caliper
CALP
5.9
5.05
16.83
Cepheid
CPHD
16.89
15.56
8.55
Illumina
ILMN
45.49
49.44
-7.99
Invitrogen
IVGN
78.53
78.8
-0.34
Luminex
LMNX
13.68
14.4
-5.00
MDS
MDZ
18.74
19.0
-1.37
Millipore
MIL
73.1
74.78
-2.25
PerkinElmer
PKI
27.53
27.03
1.85
Qiagen
QGEN
17.19
17.98
-4.39
Sequenom
SQNM
4.47
5.35
-16.45
Sigma-Aldrich
SIAL
45.83
48.21
-4.94
Thermo
TMO
52.9
52.1
1.54
Third Wave
TWTI
6.92
7.23
-4.29
Waters
WAT
62.02
63.31
-2.04
BCW Index Average  
37.96
38.58
-1.61
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.